Ultragenyx Pharmaceutical IncNASDAQ:RARE
- LAST PRICE42.5300
- TODAY'S CHANGE (%)1.4100 (3.4290%)
- Bid / Lots42.5100/ 2
- Ask / Lots42.5600/ 3
- Open / Previous Close41.3300 / 41.1200
- Day Range
- 52 Week Range
- Volume590,466
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RARE |
|---|---|---|
| 09:32 ET | 20484 | 41.32 |
| 09:34 ET | 391 | 41.34 |
| 09:36 ET | 2339 | 41.33 |
| 09:38 ET | 763 | 41.4 |
| 09:39 ET | 200 | 41.25 |
| 09:41 ET | 400 | 41.24 |
| 09:43 ET | 2146 | 41.33 |
| 09:45 ET | 1300 | 41.35 |
| 09:48 ET | 400 | 41.32 |
| 09:50 ET | 500 | 41.2925 |
| 09:52 ET | 600 | 41.32 |
| 09:54 ET | 1600 | 41.37 |
| 09:56 ET | 1100 | 41.345 |
| 09:57 ET | 500 | 41.345 |
| 09:59 ET | 1000 | 41.3568 |
| 10:01 ET | 300 | 41.43 |
| 10:03 ET | 17379 | 41.5 |
| 10:06 ET | 16000 | 41.6 |
| 10:08 ET | 4800 | 41.57 |
| 10:10 ET | 2708 | 41.55 |
| 10:12 ET | 1000 | 41.51 |
| 10:14 ET | 1060 | 41.593 |
| 10:15 ET | 500 | 41.65 |
| 10:17 ET | 1703 | 41.65 |
| 10:21 ET | 1120 | 41.665 |
| 10:24 ET | 2986 | 41.78 |
| 10:26 ET | 300 | 41.75 |
| 10:28 ET | 200 | 41.695 |
| 10:30 ET | 675 | 41.7 |
| 10:32 ET | 930 | 41.68 |
| 10:33 ET | 200 | 41.65 |
| 10:35 ET | 2100 | 41.77 |
| 10:37 ET | 4054 | 41.77 |
| 10:39 ET | 825 | 41.73 |
| 10:42 ET | 550 | 41.695 |
| 10:44 ET | 1936 | 41.62 |
| 10:46 ET | 9699 | 41.85 |
| 10:48 ET | 3495 | 41.915 |
| 10:50 ET | 5436 | 41.92 |
| 10:51 ET | 700 | 41.9798 |
| 10:53 ET | 4436 | 41.95 |
| 10:55 ET | 34177 | 41.98 |
| 10:57 ET | 25132 | 42.02 |
| 11:00 ET | 58309 | 42.13 |
| 11:02 ET | 3066 | 42.08 |
| 11:04 ET | 1705 | 42.2 |
| 11:06 ET | 2549 | 42.245 |
| 11:08 ET | 700 | 42.19 |
| 11:09 ET | 3439 | 42.34 |
| 11:11 ET | 2494 | 42.425 |
| 11:13 ET | 4553 | 42.4 |
| 11:15 ET | 1024 | 42.295 |
| 11:20 ET | 2049 | 42.36 |
| 11:22 ET | 691 | 42.4 |
| 11:24 ET | 1079 | 42.48 |
| 11:26 ET | 200 | 42.48 |
| 11:27 ET | 1700 | 42.44 |
| 11:29 ET | 100 | 42.45 |
| 11:31 ET | 52893 | 42.61 |
| 11:33 ET | 1868 | 42.555 |
| 11:36 ET | 2791 | 42.7 |
| 11:38 ET | 9241 | 42.97 |
| 11:40 ET | 3897 | 42.84 |
| 11:42 ET | 500 | 42.88 |
| 11:44 ET | 2500 | 42.7904 |
| 11:45 ET | 9442 | 42.92 |
| 11:47 ET | 31682 | 42.78 |
| 11:49 ET | 1851 | 42.85 |
| 11:51 ET | 100 | 42.92 |
| 11:54 ET | 4206 | 42.9 |
| 11:56 ET | 200 | 42.9 |
| 11:58 ET | 425 | 42.87 |
| 12:00 ET | 573 | 42.92 |
| 12:02 ET | 700 | 42.98 |
| 12:03 ET | 634 | 42.98 |
| 12:05 ET | 7510 | 42.8 |
| 12:07 ET | 2043 | 42.67 |
| 12:09 ET | 265 | 42.65 |
| 12:12 ET | 4240 | 42.75 |
| 12:14 ET | 1048 | 42.69 |
| 12:16 ET | 6994 | 42.695 |
| 12:18 ET | 715 | 42.73 |
| 12:20 ET | 536 | 42.7 |
| 12:21 ET | 3161 | 42.65 |
| 12:23 ET | 458 | 42.59 |
| 12:25 ET | 800 | 42.6537 |
| 12:27 ET | 483 | 42.66 |
| 12:30 ET | 750 | 42.73 |
| 12:32 ET | 200 | 42.73 |
| 12:34 ET | 1909 | 42.69 |
| 12:38 ET | 2281 | 42.72 |
| 12:39 ET | 284 | 42.67 |
| 12:43 ET | 2874 | 42.6 |
| 12:45 ET | 720 | 42.58 |
| 12:48 ET | 1300 | 42.56 |
| 12:50 ET | 300 | 42.57 |
| 12:52 ET | 1415 | 42.68 |
| 12:54 ET | 687 | 42.65 |
| 12:56 ET | 470 | 42.62 |
| 12:57 ET | 200 | 42.63 |
| 01:01 ET | 800 | 42.635 |
| 01:03 ET | 236 | 42.64 |
| 01:06 ET | 400 | 42.665 |
| 01:08 ET | 3254 | 42.61 |
| 01:10 ET | 562 | 42.55 |
| 01:12 ET | 700 | 42.6 |
| 01:14 ET | 200 | 42.56 |
| 01:15 ET | 600 | 42.63 |
| 01:17 ET | 300 | 42.63 |
| 01:19 ET | 2101 | 42.49 |
| 01:21 ET | 800 | 42.53 |
May 7, 2024
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference, from 4:30PM ET on Tuesday May 07, 2024 by Dow Jones
4:30PM ET on Tuesday May 07, 2024 by Dow Jones
May 6, 2024
DJ Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity, from 1:45PM ET on Monday May 06, 2024 by Dow Jones
1:45PM ET on Monday May 06, 2024 by Dow Jones
May 3, 2024
DJ Ultragenyx Pharma Price Target Maintained With a $107.00/Share by Cantor Fitzgerald, from 11:24AM ET on Friday May 03, 2024 by Dow Jones
11:24AM ET on Friday May 03, 2024 by Dow JonesDJ Ultragenyx Pharma Is Maintained at Neutral by Wedbush, from 9:43AM ET on Friday May 03, 2024 by Dow Jones
9:43AM ET on Friday May 03, 2024 by Dow Jones
May 2, 2024
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update, from 4:00PM ET on Thursday May 02, 2024 by Dow Jones
4:00PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ultragenyx Pharmaceutical Inc | 3.4B | -5.3x | --- |
Amicus Therapeutics Inc | 2.9B | -19.3x | --- |
Guardant Health Inc | 3.2B | -6.9x | --- |
Denali Therapeutics Inc | 3.0B | -21.4x | --- |
Insmed Inc | 3.7B | -4.8x | --- |
Genmab A/S | 19.8B | 24.7x | +22.71% |
Company Information
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Contact Information
- Headquarters
- 60 Leveroni CtNOVATO, CA, United States 94949-5746
- Phone
- 415-483-8800
- Fax
- 415-483-8810
Executives
- Independent Chairman of the Board
- Daniel Welch
- President, Chief Executive Officer, Director
- Emil Kakkis
- Chief Financial Officer, Executive Vice President, Corporate Strategy
- Howard Horn
- Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
- Dennis Huang
- Executive Vice President, Chief Legal Officer, General Counsel
- Karah Parschauer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $442.6M |
Shares Outstanding | 83.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-8.02 |
Book Value | $3.35 |
P/E Ratio | -5.3x |
Price/Sales (TTM) | 7.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -131.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
